small molecule

ATZUMI

DIHYDROERGOTAMINE MESYLATE

Loss of exclusivityOctober 2041latest FDA-listed patent expiry

CompanySatsuma Pharmaceuticals, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	ATZUMI
Active ingredient	DIHYDROERGOTAMINE MESYLATE
Strength	EQ 5.2MG BASE
Dosage form	POWDER
Route	NASAL
Modality	Small molecule
FDA approval	April 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11744967	October 2041	product
12102754	October 2041	product
10758532	December 2039	product
12263162	December 2039	product
10792253	August 2037	product
11872314	August 2037	product
12594273	September 2033	product

Regulatory exclusivity

Code	Expires
NP	April 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.